Takeda shareholder plans sale of 33,454 ADSs

Takeda Pharmaceutical Company Limited has a shareholder planning to sell American Depositary Shares (ADSs) through Interactive Brokers LLC on the NYSE.

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited has a shareholder planning to sell American Depositary Shares (ADSs) through Interactive Brokers LLC on the NYSE. The proposed sale covers 33,454 ADSs with an approximate aggregate value of $560,351.40 as of a planned sale date of July 13, 2026. In the prior three months, 65,890 ADSs were involved in transactions tied to Restricted Stock Unit Awards – Vested dated July 1, 2026, categorized as compensation-related activity.

Filing Explained

The filing describes a planned ADS sale by a holder, not completed issuance, proceeds, or dilution for existing Takeda holders.

The July 13 Form 144 reports a proposed sale of Takeda ADSs through Interactive Brokers; this is a notice of a planned holder sale, not evidence that the securities have been sold or that Takeda is issuing new shares.

The filing identifies the securities as ADSs and states that 65,890 were acquired from Takeda on July 1, 2026 through vested restricted stock unit awards, with compensation listed as the payment method.

The disclosed mechanics describe a disposition by the filer rather than a change to Takeda's capital structure, and the filing does not establish proceeds received, completion of the sale, or dilution for existing common holders.

The filing identifies July 13, 2026 as the approximate sale date and names the NYSE as the exchange; whether the proposed sale occurred would require a later transaction filing.

Key Figures

ADSs proposed for sale: 33,454 ADSs Aggregate value of ADSs: $560,351.40 ADSs tied to vested RSU awards: 65,890 ADSs +2 more

5 metrics

ADSs proposed for sale 33,454 ADSs Planned sale through Interactive Brokers LLC on or about July 13, 2026

Aggregate value of ADSs $560,351.40 Approximate value associated with 33,454 ADSs proposed for sale

ADSs tied to vested RSU awards 65,890 ADSs Restricted Stock Unit Awards – Vested dated July 1, 2026, categorized as compensation

Proposed sale date 07/13/2026 Date associated with the proposed ADS sale on the NYSE

RSU vesting date 07/01/2026 Date of Restricted Stock Unit Awards – Vested for 65,890 ADSs

Key Terms

American Depositary Shares (ADSs), Restricted Stock Unit Awards - Vested, compensation, Form 144

4 terms

American Depositary Shares (ADSs) financial

"American Depositary Shares (ADSs) | Interactive Brokers LLC"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Restricted Stock Unit Awards - Vested financial

"ADSs | 07/01/2026 | Restricted Stock Unit Awards - Vested."

compensation financial

"65890 | 07/01/2026 | Compensation"

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What sale of Takeda (TAK) ADSs is disclosed in this Form 144?

A shareholder intends to sell 33,454 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited, with an indicated aggregate value of about $560,351.40, through Interactive Brokers LLC on or after July 13, 2026.

What type of securities are involved for Takeda (TAK) in this filing?

The filing involves American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited, which are listed for trading on the NYSE and are to be sold through Interactive Brokers LLC.

How many Takeda (TAK) ADSs were related to recent compensation activity?

The disclosure lists 65,890 ADSs associated with Restricted Stock Unit Awards – Vested dated July 1, 2026, categorized as compensation in the section covering securities sold or involved during the past three months.

What is the approximate value of Takeda (TAK) ADSs proposed to be sold?

The planned sale covers 33,454 ADSs with an indicated aggregate value of about $560,351.40. This figure reflects the value referenced in connection with the proposed July 13, 2026 sale through Interactive Brokers LLC.

Which broker and exchange are used for the Takeda (TAK) ADSs sale?

The proposed sale of Takeda ADSs is to be executed through Interactive Brokers LLC, with the securities listed and traded on the NYSE, as indicated in the Form 144 details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 06:25 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002111535
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Takeda Pharmaceutical Company Limited
SEC File Number
Address of Issuer	1-1, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo JAPAN 103-8668
Phone	81-3-3278-2111
Name of Person for Whose Account the Securities are To Be Sold	Natalie Furney
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Global General Counsel

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	33454	560351.4	143310556	07/13/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2026	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			65890	07/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	07/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kate Huleatt, by power of attorney, for Natalie Furney
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)